Double‐blind comparison of lansoprazole 15 mg, lansoprazole 30 mg and placebo as maintenance therapy in patients with healed duodenal ulcers resistant to H2‐receptor antagonists

• Published in: Alimentary pharmacology & therapeutics 1999-07, Vol.13 (7), p.959-967
• Main Authors: KOVACS, T. O. G, CAMPBELL, D, RICHTER, J, HABER, M, JENNINGS, D. E, ROSE, P
• Format: Article
• Language: English
• Subjects: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents - administration & dosage; Biological and medical sciences; Digestive system; Double-Blind Method; Drug Resistance; Duodenal Ulcer - metabolism; Duodenal Ulcer - prevention & control; Female; Gastric Mucosa - metabolism; Gastrins - blood; Histamine H2 Antagonists - pharmacology; Humans; Lansoprazole; Male; Medical sciences; Middle Aged; Omeprazole - administration & dosage; Omeprazole - analogs & derivatives; Pharmacology. Drug treatments; Proton Pump Inhibitors; Recurrence; Treatment Outcome; United States
• ISSN: 0269-2813; 1365-2036
• DOI: 10.1046/j.1365-2036.1999.00569.x

Background : Maintenance antisecretory therapy is often used to prevent duodenal ulcer recurrence and control symptoms. This study compared the efficacy and safety of lansoprazole 15 mg and 30 mg daily with placebo in preventing ulcer recurrence in patients with a recent history of duodenal ulcer disease. Methods : Fifty‐six patients were treated with either lansoprazole 15 mg, 30 mg or placebo o.m. Results : Within 1 month of study initiation, 27% (four out of 15) of placebo‐treated patients experienced ulcer recurrence as compared to 13% (two out of 15) and 6% (one out of 18) of lansoprazole 15 mg and 30 mg treated patients, respectively. Median time to first ulcer recurrence was > 12 months in lansoprazole patients. At Month 12, significantly (P